Successful bosentan therapy for pulmonary arterial hypertension associated with hereditary hemorrhagic telangiectasia

Heart and Vessels

Volumn 26, Issue 2, 2011, Pages 231-234

  Chang, Sung A ^a   Jang, Shin Yi ^a   Ki, Chang Seok ^a   Kang, I Seok ^a   Kim, Duk Kyung ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Endothelin receptor antagonist; Hereditary hemorrhagic telangiectasia; Pulmonary arterial hypertension

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BOSENTAN; HEMOGLOBIN;

ADULT; ARTERIOVENOUS MALFORMATION; ARTERY CATHETERIZATION; ARTICLE; CASE REPORT; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG RESPONSE; ECHOCARDIOGRAPHY; EXERCISE TOLERANCE; FEMALE; GENETIC VARIABILITY; HEMOGLOBIN BLOOD LEVEL; HUMAN; LUNG ANGIOGRAPHY; LUNG ARTERY PRESSURE; MISSENSE MUTATION; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RENDU OSLER WEBER DISEASE; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; ECHOCARDIOGRAPHY, DOPPLER; EXERCISE TOLERANCE; FEMALE; HUMANS; HYPERTENSION, PULMONARY; RECEPTORS, ENDOTHELIN; RECOVERY OF FUNCTION; SULFONAMIDES; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 79955589985     PISSN: 09108327     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00380-010-0079-z     Document Type: Article

References (8)

1. Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, Kjeldsen AD, Plauchu H (2000) Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 91:66-67
2. Trembath RC, Thomson JR, Machado RD, Morgan NV, Atkinson C, Winship I, Simonneau G, Galie N, Loyd JE, Humbert M, Nichols WC, Morrell NW, Berg J, Manes A, McGaughran J, Pauciulo M, Wheeler L (2001) Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 345:325-334
3. Abdalla SA, Gallione CJ, Barst RJ, Horn EM, Knowles JA, Marchuk DA, Letarte M, Morse JH (2004) Primary pulmonary hypertension in families with hereditary haemorrhagic telangiectasia. Eur Respir J 23:373-377 (Pubitemid 38344371)
4. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:896-903 (Pubitemid 34984638)
5. Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J (2005) Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 26:858-863 (Pubitemid 41632043)
6. Fujita H, Fukumoto Y, Saji K, Sugimura K, Demachi J, Nawata J, Shimokawa H (2010) Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension. Heart Vessels 25:144-149
7. Dimitrijevic I, Ekelund U, Edvinsson ML, Edvinsson L (2009) Increased expression of endothelin ET(B) and angiotensin AT(1) receptors in peripheral resistance arteries of patients with suspected acute coronary syndrome. Heart Vessels 24:393-398
8. Bonderman D, Nowotny R, Skoro-Sajer N, Adlbrecht C, Lang IM (2006) Bosentan therapy for pulmonary arterial hypertension associated with hereditary haemorrhagic telangiectasia. Eur J Clin Invest 36(Suppl 3):71-72 (Pubitemid 44179786)